Breakthrough: AAVantgarde Bio’s AAVB-039 Gains FDA Fast Track for Stargardt Disease Therapy
Pharm'Up 
AAVantgarde Bio, a clinical-stage biotech firm focused on next-generation gene therapies for inherited retinal conditions, has revealed that the U.S. Food and Drug Administration (FDA) has awarded Fast Track Designation to its AAVB-039 gene therapy for Stargardt disease linked to biallelic ABCA4 mutations. This announcement, made on August 14, 2025, follows the FDA’s clearance of the Investigational New Drug (IND) application for AAVB-039. Stargardt disease, the leading inherited macular degeneration, causes significant vision loss in children and young adults due to toxic retinoid buildup from ABCA4 gene mutations. AAVB-039, which delivers the full-length ABCA4 protein, holds promise for all patients with these mutations.
Dr. Natalia Misciattelli, CEO of AAVantgarde, expressed enthusiasm, stating, “The Fast Track Designation for AAVB-039 highlights the critical need and transformative potential of our therapy for those affected by Stargardt disease.”
The FDA’s Fast Track initiative speeds up the development and review of treatments for serious conditions with unmet needs. AAVB-039 is currently under evaluation in the Phase 1/2 CELESTE clinical trial, assessing its safety, tolerability, and initial efficacy. Affecting an estimated 60,000 to 75,000 people in the U.S. and E.U., Stargardt disease currently lacks approved therapies, making this a pivotal step forward.
About the Author
